

If it is a gastric ulcer
the proven way to heal it
is with Biogastrone®



Biogastrone®
carbenoxolone sodium



Duodenal and gastric ulcers

These are the facts

21 hospital trials

911 patients

69-92%

success rate

CAVED-(S)

No toxic side effects ever reported
Ambulant therapy
No dietary, smoking or alcohol
restrictions
Exceptionally low cost
No salt and water retention
No age, cardiac or respiratory
restrictions
No need for antacids
Can reduce the need for surgery
with duodenal ulcer patients

Salazopyrin[®]

in the whole spectrum
of ulcerative colitis ...



*mild... moderate...
severe (fulminating)...
relapse.*

"Among measures designed to prevent relapse small doses of corticosteroids are useless, and larger doses carry the risks of the therapy. (Salazopyrin) has been shown to reduce the relapse rate greatly when used in a maintenance dose ... over a period of one year".
Brit. med. J. (1968) 2, 539-542, 605-607.

Salazopyrin (sulpha-salazine) is available as the plain 0.5 g. tablet, as the 0.5 g. EN-tab and as an 0.5 g. suppository.

Literature and detailed information on Salazopyrin are available on request.



'In our experience and
in that of other authors
photoscanning with
 ^{75}Se -selenomethionine is a
valuable diagnostic tool in the
investigation of pancreatic disease'

Br. J. Radiol., 1967, **40**: 662

In a demanding technique it is
essential that the scanning reagent
be of adequate and
consistent quality
Its continuous use for nine years
and in over 20 countries
attests to the reliability of


L-Selenomethionine- $\text{Se } 75$ supplied by
The Radiochemical Centre

L-Selenomethionine- $\text{Se } 75$ injection, Code SC.1P
Full information available on request




The Radiochemical Centre Amersham England

Gastric ulcers—endoscopic photograph



Gefarnil brings the ulcer problem down to size.



Traditional treatment in suspected or confirmed peptic ulcer cases is mostly symptomatic—geared simply to relief of pain.

Now there is Gefarnil—the unique healing agent. Its anti-ulcer properties have already been well established in animal experiments and clinical trials^{1,2,3}. Its sys-

temic action means that Gefarnil can reach ulcer sites in both stomach and duodenum, and while many other agents act by surface contact, merely providing an environment for healing, Gefarnil takes effect through its blood-tissue level, independent of conditions in the gut lumen.



The expected sequence of events with Gefarnil is as follows:

15 days—remission of symptoms (usual antacid/antispasmodic treatment advisable during this period)
30 days—ulcers no longer detectable radiographically (but may still be evident endoscopically)
60 days—ulcers no longer detectable endoscopically.

Only minor transient side effects occur with Gefarnil, which can thus be used with confidence not only in confirmed but also in suspected ulcer patients.

Gefarnil* is presented as capsules, each containing 50 mg. Gefarnate, and as injection solution, 50 mg. per ml.

Further information available on request.

¹ Arch. int. Pharmacodyn (1964), **147**, 113. ² Minerva Gastroenterologica (1967), **13**, 157. ³ 4th World Congress Gastroenterology (1970).



Gefarnil

60 DAYS' TREATMENT...THE RELIEF OF A LIFETIME



* trademark



The CROOKES
Laboratories Limited
Basingstoke, Hants

DISEASES OF THE GASTRO-INTESTINAL TRACT

Edited by **W. R. O. GOSLINGS, M.D.,**

Head of the Department of Microbial Diseases, Leiden University Hospital

1970

134 pages

58 illustrations

£4.00

This is the latest volume in the **Boerhaave Series for Postgraduate Medical Education**. It contains the experience of members of the medical faculties of the Universities of Leiden and Edinburgh on diagnostic, therapeutic and fundamental aspects of diseases of the gastro-intestinal tract. The majority of the papers are of direct clinical importance, and in all others the investigations were prompted by problems related to clinical conditions.

Published by

E. & S. LIVINGSTONE, Teviot Place, Edinburgh

TODAY'S DRUGS

The problem facing the prescribing doctor today is choice. Catalogues of drugs—no matter how detailed—are of little help unless accompanied by advice on which drug to give for what condition. So this new edition of "Today's Drugs" not only gives a full account of the drugs but also includes clear accounts of the management of common conditions such as urinary infections and epilepsy.

The new edition differs from the earlier one in other ways. It deals with only three subjects— infections, vitamin deficiencies and anaemias, and disorders of the nervous system. Further volumes will be published at intervals of about a year, and by the time the whole field of therapeutics has been covered this first volume will have become obsolete and due for replacement. In order to further emphasize the ephemeral nature of books on therapeutics—and to cut costs—the book is a paperback.

Demy Octavo

Paperback

224 pages

Price £1.00 (U.S.A. \$3.00) including postage

ORDER YOUR COPY NOW FROM

The Publisher, **BRITISH MEDICAL JOURNAL**, B.M.A. House,
Tavistock Square, London WC1H 9JR, or through any leading bookseller

***The combative role
of Noxyflex against bacteria
is seen to be singularly effective
when compared
with the whole barrage
of alternative treatments***

When Noxyflex is applied directly to the site of existing or potential infection its effectiveness is undeniable. The latest Noxyflex literature contains a comparison of 'percentages' which points to the superiority of Noxyflex when compared with alternative treatments. Have you a copy?



Noxyflex
Geistlich Chester

2.5G. Noxytiolin and 10 mgm. Amethocaine HCl

DUOGASTRONE[®] CAPSULES

carbenoxolone sodium

"... heal duodenal ulcers in ambulant patients, without recourse to expensive and overloaded hospital facilities".

Gut 1970, **11**, 171-175

Radiological and Clinical Assessment at 12 weeks.

Radiological Changes	Healed	Improved	No Change	Worse
Control Group	0	0	14	0
DUOGASTRONE Group	4	4	6	0

Final Clinical Comment	Marked Improvement	Little or No Change	Worse
Control Group	0	14	0
DUOGASTRONE Group	13	1	0

The therapeutic action of DUOGASTRONE is quite different from that of traditional remedies for peptic ulcer. It has no effect upon gastric motility or acid secretion, but appears to act directly upon the ulcerated mucosa, probably by increasing the production of adherent mucus and encouraging epithelialisation as BIOGASTRONE does in the stomach.

The therapeutic benefits of DUOGASTRONE—

- Speeds the healing of duodenal ulcers
- Relieves symptoms within a few days
- No dietary restrictions are necessary
- Patients on DUOGASTRONE therapy
 - lead a normal, working life



Full information available on request from

BERK PHARMACEUTICALS LTD.
GODALMING & SHALFORD,
SURREY

Made under licence from
Biorex Laboratories Ltd., London.
British Patent Nos. 843,133 and
1,093,285. ® Regd. Trade Mark. J 3228

RIFOCIN[®]-M


rifamide LEPETIT

in BILIARY TRACT INFECTIONS

"... it is unique in its action in acute cholecystitis and other bacterial diseases of the biliary tract, for which it is the only specific antibiotic."¹

"A much higher proportion of the organisms found in cholangitis would be expected to be inhibited by this drug than by other antibiotics that achieve effective bile levels..."²

RIFOCIN-M BILIARY LEVELS AND MIC'S OF HOSPITAL ISOLATES



- * Active against penicillinase-producing organisms.
- * No cross-resistance or cross-allergenicity with other antibiotics has been demonstrated.
- * Well tolerated. No toxic reactions have been reported.
- * Dose: 150 mg intramuscularly every 8-12 hours.

RIFOCIN-M (rifamide) is a member of the RIFAMYCINS—a new group of antibiotics discovered and developed in the Research Laboratories of LEPETIT.

References: 1. *Med. J. Aust.*, 1966, **1**, 1-7. 2. *Brit. J. Pharmacol.*, 1967, **31**, 506-512.

Full information is available on request.



LEPETIT Pharmaceuticals Ltd.

Nicholson House, High Street, Maidenhead, Berks. Tel: Maidenhead 32277

MASSON & CIE — Editeurs. 120 Boulevard Saint Germain, 75 - PARIS 6°

The FIRST book to cover ALL aspects of . . . **Advanced Gastrointestinal Cancer**

Clinical Management and Chemotherapy

BY

Charles G. Moertel, M.D., and Richard J. Reitemeier, M.D.

Although the greater portion of the book is devoted to clinical research programs in chemotherapy and radiation therapy, the authors are keenly aware of the practical day-to-day problems met by the physician as he is called upon to administer supportive and symptomatic care. Special sections are devoted to pain control, management of edema and ascites, the control of nausea and vomiting, nutritional measures, assisting the patient's family, and pre-terminal care. Experienced specialists describe the palliative techniques employed by the general surgeon, the radiation therapist, the neurosurgeon, and anesthesiologist.

The second part of the book concerns the chemotherapy of advanced gastrointestinal cancer. Therapeutic agents, the fluorinated pyrimidines, are discussed in great detail including their administration, the relationship of their toxicity to the regression of cancer, and the clinical features influencing therapeutic responsiveness.

By **CHARLES G. MOERTEL, M.D., and RICHARD J. REITEMEIER, M.D.**, both of the Mayo Graduate School of Medicine (University of Minnesota). With Seven Contributors from the Mayo Clinic. 236 pp., 48 illus., \$15.00

Also available

Dreiling, Janowitz and Perrier

PANCREATIC INFLAMMATORY DISEASE

A Physiologic Approach

"... a wealth of clinical experiences ... are presented with clarity and authority ... There are a number of good clear line drawings diagramming the operation in current use for chronic pancreatitis. This one short volume will become a useful reference source to everyone interested in pancreatitis ... and in this area it provides an outstanding current review."
—S.G. & O.

By **DAVID A. DREILING, M.D., and HENRY D. JANOWITZ, M.D.**, both of Mt. Sinai Hospital, New York; and **CLAUDE V. PERRIER, M.D.**, Clinique et Universitaire de Therapeutique, Geneva. 250 pp., 82 illus., \$10.50

Durham

ENCYCLOPEDIA OF MEDICAL SYNDROMES

"Once a physician has familiarized himself with this book he would probably not want to be without it." *J.A.M.A.*

"... an indispensable volume for anyone wishing to increase his knowledge while practicing medicine. It should be readily at hand for reference." *Archives of Internal Medicine.*

By **ROBERT H. DURHAM, M.D., F.A.C.P.**, Henry Ford Hospital, Detroit. 644 pp., \$15.00

ORDER YOUR COPIES FROM

HARPER & ROW, Publishers
49 East 33 Street

Medical Department
New York, N.Y., U.S.A. 10016